Context: Squamous cell carcinoma (SCC) is the second most common skin cancer. Ultraviolet radiation (UVR) exposure, its most important risk factor, has mostly been investigated in cross-sectional study designs. This study presents a comprehensive and longitudinal examination of determinants of SCC, including photoageing. Objective: To examine the determinants of SCC and its precursor condition of photoageing. Above all, the objective was to investigate the interplay of phenotypic traits; occupation and leisure-time sun exposure patterns; and personal exposures, in particular, tobacco smoking and life course sun exposure, upon the risk of SCC and photoageing. Setting and Design: This investigation formed part of a large community-based, long-term cohort study of skin cancer. The Nambour Skin Cancer Study (forthwith, the Nambour Study) began in 1986 and concluded in 2007. In 1986 a random sample of 2095 people (aged 20-69 years) from Nambour, Queensland participated in a skin cancer survey. In 1992, a 5 year field trial to assess the preventive actions of sunscreen and beta-carotene was initiated (n=1621). Regular full skin examinations were conducted to determine the presence of skin cancer and actinic skin damage. In 1994, participants detailed their life course sun exposure (n=1290). After the trial ended in 1996, participants continued to complete regular questionnaires and ascertainment of skin cancers continued to 2007. Participants: The participants were 1339 unselected adults aged 25 to 75 years who had taken part in the Nambour Study in 1992 and consented to the follow-up study. Methods: Life course sun exposure hours were estimated from questionnaires and the approximate UVR exposure for Nambour (latitude 26S) was determined. Descriptive analyses examined patterns of exposure within the population. Factors influencing the severity of photoageing were also investigated. Informed by these analyses, relative risks were calculated for determinants of SCC and population attributable risk percentage (PAR%) for key modifiable risk factors. To investigate tobacco smoking as a risk factor for SCC, systematic review and meta-analysis were performed. Exposure measures: Pigmentary phenotype, estimated UVR exposure, tobacco smoking, sun-related behaviours, e.g. sunscreen use. Outcome measures: Incident and histologically proven SCC of the skin from 1992 to 2007 was the main outcome assessed. Photoageing, assessed clinically and micro-topographically (Beagley and Gibson scale), was an intermediate outcome measure and an objective measure of cumulative sun exposure in the final SCC analysis. Results: Examination of self-reported UVR revealed mean annual exposures were highest in early life and older adulthood (older than 60 years.) Women reported spending less time in the sun than men in all stages of life (p<0.05) and the more sun-sensitive the person’s skin type, the less sun exposure was reported at each life stage. The role of tobacco smoking in cutaneous SCC was reviewed in the published literature and a small positive association was noted in the meta-analysis. However, few studies had adjusted, or adjusted adequately, for sun exposure. Within the Nambour Study, with adjustment for age, sex, skin phenotype, lifetime sun exposure, current and former smoking had no association with SCC (RR 1.2, 95%CI 0.7, 2.0 and RR 1.1, 95%CI 0.8, 1.5, respectively compared with lifelong non-smokers). In this study population, with moderate to severe photoageing at study baseline, increasing age, male sex, a sun-sensitive phenotype were found to increase the odds of more severe actinic damage (p<0.05). High or very high UVR exposure in adulthood predicted a greater severity (OR 2.2, 95%CI 1.3, 4.0). Finally, the determinants of SCC were examined. Increasing age (4% increase per year of life, 95%CI 3% to 5%), male sex (RR 1.4, 95%CI 1.1, 1.9) and fair skin (RR 4.7 95%CI 2.0, 11.4) were associated with SCC. Having light eye colour and fair or red hair also significantly increased SCC risk. Recalled life course sun exposure overall was not found to be associated with SCC. Signs of actinic damage at baseline were, however, very strongly associated with SCC. Recent sun exposure, defined as that reported in the period (1-2 years) before the occurrence of SCC or for those unaffected at the end of the study, was also examined. A strong positive association was found between high recent exposure and SCC (RR 2.1, 95%CI 1.3, 3.3). PAR% estimates of prominent modifiable risk factors for SCC suggested considerable potential for reduction in incidence for at-risk populations if recent sun exposure were reduced. Conclusions: Subjective measures of solar UVR exposure and objective measures of photoageing varied according to personal and phenotypic factors. The interplay between risk factors observed here highlight the need to control for confounding in investigating solar factors as causes of skin cancer. Although SCC occurred on the background of high cumulative UVR exposure, which was best determined with objective rather than recalled measures, recent UVR exposure was also important. Self-reported recent exposure being less subject to recall bias than reported life course exposure may have partly influenced this, but the impact of UVR acting as a tumour initiator and promoter is also likely to explain the relation of SCC to sun exposure in the recent past.

Diss. (sammanfattning) Uppsala : Univ., 2003. / Härtill 6 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 4 uppsatser.

Thesis (M.S.)--University of Texas at El Paso, 2009. / Title from title screen. Vita. CD-ROM. Includes bibliographical references. Also available online.

Thesis (M.Sc.)--Memorial University of Newfoundland, 1999. / Restricted until November 2000. Bibliography: leaves 114-123.

Thesis (M.Sc.)--Memorial University of Newfoundland, 2003. / Bibliography: leaves 107-127.

The specialised nature of the stratum corneum makes it an efficient barrier to foreign substances, including drug molecules. Therefore, cutaneous drug absorption is a slow and complex process of which stratum corneum penetration is the rate limiting step. The rate and extent of stratum corneum penetration by a drug compound depends greatly on the presence of penetration enhancing/retarding excipients and therefore the clinical outcomes of a product rely greatly on the components and quality of the formulation. Hence, establishing bioequivalence between topical products is crucial to ensure that patients receiving multisource drug products are assured of the same efficacy and safety as the brand product. Since locally acting topical formulations do not target the systemic circulation, conventional methods of assessing bioequivalence using plasma levels are not appropriate. Consequently, the current regulatory guidelines require comparative clinical trials to be carried out to show bioequivalence between topical products. As these studies are very expensive and time consuming, the development of a more direct and relatively rapid and inexpensive method for determining bioequivalence between topical products is required. Clotrimazole is an anti-fungal agent where the target site of action is in the stratum corneum. In this work, tape stripping, which involves the sampling of stratum corneum, was investigated as a tool for the determination of bioequivalence between topical clotrimazole products. The tape stripping method involved the analysis of each tape strip individually and standardization of stratum corneum thickness between subjects was carried out using TEWL measurements. This approach provided detailed information regarding the amount of clotrimazole present in the stratum corneum as well as the extent of drug penetration. Prior to the tape stripping studies an HPLC method was developed for the quantitative analysis of clotrimazole from the tape strip samples. This method was shown to be accurate and reproducible across the required range. It was also shown to be selective for clotrimazole in the presence of possible interfering substances such as those present in the tape adhesive and also skin components. The bioequivalence studies were conducted using a single “uptake” time point. In order to determine an appropriate dose duration for these studies a novel approach was employed, involving a preliminary dose duration study. For the bioequivalence investigations, Canesten® Topical cream was used as both test and reference products to determine if the method was capable of showing bioequivalence. Subsequently, Canesten® Topical cream was also compared to a 1% gel formulation to determine if the method could detect formulation differences. The conventional BE limits of 0.8 – 1.25 were used for the assessment of BE, however, the clinical relevance of using these limits for dermal studies is debatable since they are derived from oral pharmacokinetic studies. Therefore, the data from the tape stripping investigations were also assessed using more realistic limits of 0.75 – 1.33 and even 0.7 – 1.44. In addition to the tape stripping studies a novel method of determining the amount of drug present in the stratum corneum, the “Residual Method”, was investigated. This method involved assaying the amount of clotrimazole found in the residual formulation after a specified dose duration had elapsed and subtracting that amount from the amount of clotrimazole initially applied. The results of tape stripping investigations showed that, if the study is sufficiently powered, tape stripping may be used to determine bioequivalence according to the conventional limits, as well as possibly detect formulation differences between different clotrimazole products. Bioequivalence assessment using the widened intervals showed that fewer subjects were required to achieve a sufficient statistical power. The variability associated with this method was acceptable and tape stripping may therefore have the potential to be used as a BE tool in a regulatory setting for clotrimazole or other antifungal topical formulations. The “Residual Method” also showed promising results as a bioequivalence tool, but further investigation and extensive validation of this method is required before it can be suggested as a regulatory method. The results of these studies have clearly indicated that tape stripping has the potential to be used as an alternative to comparative clinical trails for the assessment of bioequivalence between clotrimazole formulations and also to assess bioequivalence between other antifungal products.

La leishmaniose cutanée (LC) est une infection parasitaire classifiée par l’Organisation de Santé Mondiale (WHO) comme étant une des maladies tropicales négligées non-contrôlées. Dans la région du Moyen Orient, la LC est généralement endémique en Syrie et elle est causée principalement par Leishmania tropica et Leishmania major. La LC a été récemment introduite à des pays non endémiques, suite au déplacement intense des réfugiés Syriens échappant à la crise. Les interventions thérapeutiques contre la LC incluent des traitements locaux, systémiques et physiques. En revanche, le risque élevé de sélection et de résistance des parasites aux traitements actuels suscitent une quête sérieuse, pour trouver de nouvelles approches thérapeutiques. L’Imiquimod est un composé immunomodulateur approuvé pour utilisation clinique, et présente une efficacité vis-à-vis de certaines espèces de Leishmania. Dans cette étude, notre intérêt s’est focalisé sur l’efficacité d’un analogue de l’Imiquimod, l’EAPB0503, contre les stades promastigotes et amastigotes de L.tropica et L.major.Nos résultats montrent que l’Imiquimod et particulièrement l’EAPB0503 affectent les deux espèces. L’Imiquimod affecte majoritairement la motilité des promastigotes des deux espèces, alors que l’EAPB0503 affecte la motilité des promastigotes de L. major mais surtout l’invasion des promastigotes de L. tropica dans les macrophages. Les deux composés réduisent la réplication des amastigotes, avec un effet plus prominent de l’EAPB0503. Cet effet est médié par l’augmentation de l’expression du récepteur toll-Like-7 (TLR7), particulièrement pour l’Imiquimod et d’une manière moins importante pour l’EAPB0503. Les deux composés induisent l’activation de la voie de signalisation canonique de NF-κB. Ceci conduit à une production des cytokines pro-inflammatoires, et une diminution des cytokines anti-inflammatoires expliquant l’activité leishmanicide des deux composés. L’EAPB0503 semble agir via un autre TLR que l’imiquimod, comme il induit une expression plus élevée des transcrits TLR8 et TLR9, conférant une protection contre l’infection.Collectivement, nos résultats montrent l’effet de l’Imiquimod contre l’espèce la plus aggressive, L. tropica, et souligne l’activité plus puissante de l’EAPB0503 contre les deux espèces. De plus, cette étude montre le mécanisme d’action de ces deux composés, qui vraisemblablement activent des TLRs différents, mais finissent par induire la voie NF-κB et la réponse immunitaire correspondante. Ces résultats soulignent l’importance des drogues immuno-modulatrices contre la LC et ouvrent des perspectives sur des études précliniques puis cliniques de ces composés. / Cutaneous Leishmaniasis (CL) is a parasitic infection classified by the WHO as one of the most uncontrolled spreading neglected diseases. In the Middle East Region, CL is mostly endemic in Syria where it is mainly caused by Leishmania tropica and Leishmania major. CL has been lately introduced to under endemic countries, following the large-scale displacement of refugees from Syria fleeing the crisis. Therapeutic interventions against CL include local, systemic and physical treatments. However, the high risk for selection and spread of drug-resistant parasites is high; consequently new therapeutic approaches are still needed. Imiquimod is an FDA approved immunomodulatory compound with a tested efficacy against some leishmania species. In this study, our interest was to investigate the efficacy of an Imiquimod analog, EAPB0503 in comparison to the original compound, against promastigote and amastigote stages of L.tropica and L.major.We showed that Imiquimod affects the motility of promastigotes of both strains. EAPB0503 affected L. major promastigotes’ motility and impaired the invasion of L.tropica promastigotes into macrophages. Both drugs reduced amastigote replication, with a higher potency of EAPB0503. This activity is due to the upregulation of Toll-Like Receptor-7 (TLR7), mainly by Imiquimod, and to a lesser extent by EAPB0503. Importantly, both drugs activated the NF-κB canonical pathway leading to production of pro-inflammatory cytokines and upregulation of i-NOS levels. A decrease of anti-inflammatory cytokines secretion was obtained, explaining the leishmanicidal activity of both drugs. Importantly, EAPB0503 led to a prominent increase in TLR8 and TLR9 transcripts, presumably conferring protection against the infection.Collectively, our findings show the effect of Imiquimod against both strains especially, the aggressive L. tropica strain. We also show that EAPB0503 displays a more potent in vitro leishmanicidal activity than Imiquimod. These drugs seemingly activate different TLRs, but both activate the canonical NF-κB pathway and its subsequent mediated immune response. These results highlight the promising effect of immunomodulatory drugs against CL and warrant an in depth in vivo preclinical then clinical studies of these compounds.

Doctor of Philosophy / Department of Anatomy and Physiology / Thomas J. Barstow / The primary aim of this dissertation was to describe the changes in microvascular hematocrit, as total[hemoglobin+myoglobin] (T[Hb+Mb] measured with near-infrared spectroscopy (NIRS), during post-occlusive reactive hyperemia (PORH). Mechanisms of reactive hyperemia within skeletal muscle were also explored. The investigation detailed in Chapter 2 of this dissertation found that the differing time courses of the kinetic responses of both oxy- and deoxy[Hb+Mb], are related to changes in T[Hb+Mb]. We also determined that adipose tissue thickness had no effect on a purely temporal analysis of NIRS data. In Chapter 3 we observed that brachial artery reactive hyperemia preceded changes in T[Hb+Mb] during reactive hyperemia. Assuming that myoglobin remained constant, we posited that changes in T[Hb+Mb] must reflect alterations in red blood cell concentration in the microvasculature, i.e., microvascular hematocrit. In Chapter 4 comparisons were made between brachial artery blood flow, cutaneous and skeletal muscle flux and T[Hb+Mb]. The conduit artery response was faster than the microvascular responses in all tissues. Within skeletal muscle, time to peak and the time constant for the on-kinetics were faster in T[Hb+Mb] compoared with intramuscular flux as measured with intramuscular laser-Doppler. We observed no differences in temporal responses between cutaneous and intramuscular measures and suggested that in a purely temporal analysis the cutaneous microvasculature could serve as an analog for the skeletal muscle microvasculature. Finally, in Chapter 5 we found that prostaglandin inhibition with ibuprofen altered the initial T[Hb+Mb] response during PORH without impacting cutaneous flux or brachial artery blood flow. Chapter 5 also discussed that the addition of a wrist cuff to our standard instrumentation prevented the accumulation of T[Hb+Mb] during the occlusion period.

--- / ---